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ABSTRACT
Objectives: To investigate whether elevated urinary HAI-1, EpCAM and EGFR 
are independent prognostic biomarkers within non-muscle-invasive bladder cancer 
(NMIBC) patients, and have utility for risk stratification to facilitate treatment 
decisions.
Results: After accounting for EAU risk group in NMIBC patients, the risk of BC-
specific death was 2.14 times higher (95% CI: 1.08 to 4.24) if HAI-1 was elevated 
and 2.04 times higher (95% CI: 1.02 to 4.07) if EpCAM was elevated. The majority of 
events occurred in the high-risk NMIBC group and this is where the biggest difference 
is seen in the survival curves when plotted for EAU risk groups separately. In MIBC 
patients, being elevated for any of the three biomarkers was significantly associated 
with BC-specific mortality after accounting for other risk factors, HR = 4.30 (95% 
CI: 1.85 to 10.03).
Patients and Methods: Urinary levels of HAI-1, EpCAM and EGFR were measured 
by ELISA in 683 and 175 patients with newly-diagnosed NMIBC and MIBC, respectively, 
recruited to the Bladder Cancer Prognosis Programme. Associations between 
biomarkers and progression, BC-specific mortality and all-cause mortality were 
evaluated using univariable and multivariable Cox regression models, adjusted for 
European Association of Urology (EAU) NMIBC risk groups. The upper 25% of values 
for each biomarker within NMIBC patients were considered as elevated. Exploratory 
analyses in urine from MIBC patients were also undertaken.
Conclusion: Urinary HAI-1 and EpCAM are prognostic biomarkers for NMIBC 
patients. These biomarkers have potential to guide treatment decisions for high-risk 
NMIBC patients. Further analyses are required to define the roles of HAI-1, EpCAM 
and EGFR in MIBC patients. 
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 38), pp: 25244-25253
              Research Paper
Oncotarget25245www.oncotarget.com
INTRODUCTION
High-risk non-muscle-invasive bladder cancer 
(HR-NMIBC [1]) represents over 30% of all incident 
bladder cancers [2]. These patients are at considerable 
risk of progression [1, 3], and 20–30% will die from 
bladder cancer within 5-years [4–6]. Current guidelines 
recommend induction and maintenance intravesical BCG 
or upfront radical cystectomy for highest risk disease [1], 
treatments with markedly different morbidity, mortality 
and long-term patient burden. There are no validated 
biomarkers that can facilitate treatment decisions [7], and 
the field has been plagued by unstable BCG supply for 
6-years [8].
Shedding of the extracellular domains (ectodomains) 
of transmembrane proteins is recognised as an important 
cancer-related phenomenon [9–11]. We have previously 
reported the identification of the shed ectodomains of HAI-
1, EpCAM and EGFR in the urine of bladder cancer patients 
[12–14]; elevated urine levels of the shed ectodomains of 
EpCAM and EGFR are associated with worse bladder 
cancer (BC) specific survival [13, 14]. HAI-1 has not 
previously been investigated as a prognostic biomarker 
in BC. Mechanistically, ectodomain shedding is mediated 
by transmembrane proteases which demonstrate substrate 
specificity and tight regulation [10, 15]. Hence, levels of 
these ectodomains in urine may represent measurable 
indicators of disease-specific post-transcriptional 
phenomena. 
The present study explores the associations between 
urinary levels of HAI-1, EpCAM and EGFR and disease 
progression and mortality in a cohort of 858 patients (683 
NMIBC patients and 175 MIBC patients) from the West 
Midlands’ Bladder Cancer Prognosis Programme (BCPP 
[16]) in order to investigate their utility for risk-stratifying 
NMIBC patients (and HR-NMIBC patients in particular). 
We included MIBC patients since these tumours share 
many biological similarities with HR-NMIBC [17], and so 
any prognostic signal for these biomarkers in HR-NMIBC 
patients would also be expected in MIBC patients; 
furthermore, the investigation of the relationship between 
these biomarkers and mortality in MIBC patients acts as an 
internal corroboration of findings. These biomarkers were 
originally discovered within subsets of BCPP patients [12–
14], and the current work represents comprehensive repeat 
ELISA measurements and analysis within all available 
BCPP urine samples to confirm our preliminary findings 
using more data, and also to investigate biomarker 
associations within NMIBC patients specifically. 
RESULTS
Summary characteristics
After exclusions, there were 858 patients remaining 
in the dataset, of which 683 were diagnosed with NMIBC 
and 175 with MIBC (Figure 1). Patient and tumour 
characteristics for NMIBC and MIBC patients are shown 
in Table 1. The median age was 71 years and 75 years in 
NMIBC and MIBC patients, respectively. The proportion 
of females was 20–21% in both groups. In the NMIBC 
group, 12% of patients had concomitant CIS, whereas 
this was higher in the MIBC group (21%). Patients were 
followed up for a median duration of 4.5 years and 3.8 
years in the NMIBC and MIBC groups, respectively. Of 
all recorded deaths, 27% and 67% were related to BC 
rather than treatment or other causes in NMIBC and MIBC 
groups, respectively.
Of the 858 patients, 496 patients (57.8%), 359 
(41.8%) and 387 (45.1%) had been used in previous 
analyses of urinary EGFR, EpCAM, HAI-1 in BC, 
respectively [12–14]. The previous analyses had only 
considered HAI-1 as a diagnostic biomarker, and not 
as a prognostic biomarker. Here we utilise more patient 
samples, and all of the assays were run in a single series of 
replicated experiments to generate a more comprehensive 
data set.
Prognostic value of HAI-1, EpCAM & EGFR in 
NMIBC patients
Using the upper quartile of biomarker values in 
NMIBC patients, the cut-offs for an elevated biomarker 
result were defined as 2 ng/mg creatinine, 29 pg/mg 
creatinine and 392 pg/mg creatinine for HAI-1, EpCAM 
and EGFR, respectively. The number and proportion of 
elevated biomarker values across EAU risk groups is 
shown in Table 2. The unadjusted and adjusted (for EAU 
risk group) hazard ratios (HRs) from Cox models for each 
biomarker and for each outcome are shown in Table 3 (full 
multivariable estimates provided in Supplementary Tables 
1–4). Elevated EpCAM and HAI-1 are prognostic for 
BC-specific death after accounting for EAU risk group, 
HR = 2.04 (95% CI: 1.02 to 4.07) & HR = 2.14 (95% 
CI: 1.08 to 4.24), respectively. The majority of events 
occur in the high-risk NMIBC group and this is where 
the biggest difference is seen in the survival curves when 
plotted for EAU risk groups separately (Figure 2). The 
same is seen for all-cause mortality, although there is more 
separation between survival curves in high-risk NMIBC 
(Figure 3). Although the highest adjusted HR observed 
for BC-specific mortality is 2.41 (95% CI: 1.14 to 5.07) 
for “any biomarker elevated” (Table 3), the separation 
between survival curves is similar to that for HAI-1 alone 
(Figure 2); the unadjusted and adjusted HRs for “any 
biomarker elevated” are no greater than for HAI-1 when 
assessing all-cause mortality (Table 3 and Figure 3). There 
appeared to be no difference in treatment modality utilised 
between patients with normal and elevated biomarker 
values (Supplementary Table 5).
The association of elevated biomarker levels with 
the risk of progression from NMIBC to MIBC is weaker 
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than for death, HAI-1 HR = 1.85 (95% CI: 1.07 to 3.20) 
unadjusted and HR = 1.69 (95% CI: 0.97 to 2.93) adjusted 
for EAU risk group; neither EpCAM nor EGFR reached 
significance (Table 3). The progression-free survival 
curves according to each biomarker in each risk group are 
shown in Supplementary Figure 1. 
Prognostic value of HAI-1, EpCAM & EGFR in 
MIBC patients
A higher proportion of patients had elevated 
biomarkers in the MIBC group with 61.7% elevated for 
HAI-1, 53.1% elevated for EpCAM and 58.3% elevated 
for EGFR. To maintain uniformity with the NMIBC 
analyses, we used individual components of the EAU risk 
stratification for multivariable analyses: grade, tumour 
size and multiplicity, and the presence or absence of CIS 
(all patients newly-diagnosed, stages T2+) [3]. Since 
these factors are not entirely relevant for prognostication 
in MIBC, these represent exploratory analyses only. 
Multivariable Cox models adjusting for these risk 
factors suggest HAI-1 and EGFR to be independent 
prognostic factors for BC-specific mortality (Table 4; 
full multivariable models in Supplementary Tables 6–9). 
Being elevated for any of the three biomarkers was 
significantly associated with BC-specific mortality after 
accounting for other risk factors, HR = 4.30 (95% CI: 
1.85 to 10.03), with the survival curves showing early 
separation (Supplementary Figure 2).
DISCUSSION
We have demonstrated that elevated levels of 
urinary HAI-1 and EpCAM are associated with BC-
specific mortality in high-risk NMIBC patients: each 
Figure 1: Flow diagram showing exclusions made prior to analysis.
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biomarker is associated with increased risk of death from 
disease within 5-years (adjusted for EAU risk group). 
Exploratory analyses demonstrate an association between 
elevated urinary HAI-1 and EGFR and increased risk of 
death in MIBC patients. For HAI-1, these associations 
have not been reported previously.
The functions and biology of EpCAM and EGFR 
have been described elsewhere [12–14]. HAI-1 is a 
Table 1: Patient and tumour characteristics in non-muscle-invasive and muscle-invasive bladder cancer patients
NMIBC (N = 683) MIBC (N = 175)
Patient demographics n (%) n (%)
Age, years* 70.6 [62.9 to 77.3] 75.1 [66.1 to 88.2]
Sex
   Male 540 (79.1) 140 (80.0)
   Female 143 (20.9) 35 (20.0)
Smoking
   Smoker 124 (18.2) 35 (20.0)
   Ex-smoker 364 (53.3) 109 (62.3)
   Never smoked 148 (21.7) 16 (9.1)
   Missing 47 (6.9) 15 (8.6)
Cancer Information
Tumour size, cm* 2 [1 to 3] 4 [3 to 6]
Grade
   Grade 1 198 (29.0) 0 (0)
   Grade 2 260 (38.1) 10 (5.7)
   Grade 3 225 (32.9) 165 (94.3)
Stage
   pTa 471 (69.0) 0 (0)
   pT1 212 (31.0) 0 (0)
   pT2+ 0 (0) 175 (100.0)
CIS
   Yes 83 (12.2) 36 (20.6)
   No 372 (54.5) 82 (46.9)
   Not stated 228 (33.4) 57 (32.6)
Follow-up Median (95% CI for median) Median (95% CI for median)
Follow-up duration, years 4.5 (4.3 to 4.7) 3.8 (3.2 to 4.2)
Death+
   No 558 (81.7) 47 (26.9)
   Yes 125 (18.3) 128 (73.1)
     Death related to bladder cancer 34 (27.2) 86 (67.2)
     Death related to treatment 1 (0.8) 4 (3.1)
     Death related to other causes 89 (71.2) 37 (28.9)
     Cause of death missing 1 (0.8) 1 (0.8)
Progression+
   Yes 57 (8.3) -
   No 453 (66.3) -
   Missing 173 (25.3) -
*Median [interquartile range] reported for non-normal continuous variable.
+Frequency (percentage) for categorical variable.
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Table 2: Number and proportion of NMIBC patients in each EAU risk group (and overall) with an elevated biomarker 
result
Low risk (n = 123) Intermediate risk  (n = 237) High risk (n = 323)
Across all risk groups 
(n = 683)
EGFR 28 (22.8%) 46 (19.4%) 96 (29.7%) 170 (24.9%)
EpCAM 13 (10.6%) 43 (18.1%) 114 (35.3%) 170 (24.9%)
HAI-1 18 (14.6%) 43 (18.1%) 110 (34.1%) 171 (25.0%)
Table 3: Cox model estimates for biomarkers from univariable (unadjusted) and multivariable models in NMIBC 
patients (N = 683 for BC-specific and all-cause mortality, N = 510 for progression)
BC-specific mortality All-cause mortality Progression
Unadjusted Adjusted for EAU risk group Unadjusted Adjusted for EAU risk group Unadjusted
Adjusted for EAU risk 
group
HR*  
(95% CI) P-value
HR*  
(95% CI) P-value
HR*  
(95% CI) P-value
HR*  
(95% CI) P-value
HR  
(95% CI) P-value
HR  
(95% CI) P-value
Elevated 
EGFR
2.08  
(1.03 to 4.19) 0.040
1.76 
(0.87 to 3.56) 0.115
1.84 
(1.27 to 2.67) 0.001
1.70 
(1.17 to 2.48) 0.005
1.16  
(0.63 to 2.12) 0.629
1.08 
(0.59 to 1.99) 0.798
Elevated 
EpCAM
2.92  
(1.48 to 5.76) 0.002
2.15 
(1.08 to 4.29) 0.030
1.94 
(1.34 to 2.81) <0.001
1.71 
(1.18 to 2.50) 0.005
1.50  
(0.84 to 2.68) 0.166
1.33 
(0.74 to 2.40) 0.341
Elevated 
HAI-1
2.59  
(1.31 to 5.12) 0.006
2.15 
(1.09 to 4.26) 0.028
1.95 
(1.35 to 2.81) <0.001
1.77 
(1.22 to 2.55) 0.002
1.85  
(1.08 to 3.20) 0.026
1.69 
(0.97 to 2.93) 0.064
Any 
biomarker 
elevated
3.05 
(1.45 to 6.40) 0.003
2.45 
(1.16 to 5.17) 0.019
1.99  
(1.39 to 2.86) <0.001
1.81 
(1.26 to 2.60) 0.001
1.80 
(1.07 to 3.04) 0.027
1.67 
(0.98 to 2.83) 0.058
*Hazard ratios are relative to baseline categories which are normal EGFR, normal EpCAM and normal HAI-1.
Figure 2: Bladder cancer specific survival curves for normal and elevated biomarker test results for (A) EGFR, (B) EpCAM, (C) HAI-1 
and (D) combination of all three biomarkers, within each EAU risk group in NMIBC patients.
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membrane-associated Kunitz-type serine proteinase 
inhibitor that inhibits hepatocyte growth factor activator, 
matriptase, and other members of the S1 family of trypsin-
like serine proteases. The mechanisms of ectodomain 
shedding, and the interplay of membrane-bound proteases 
and their regulatory molecules [15], add an extra layer 
of complexity to the molecular pathology of BC [14]. 
Thus, measuring HAI-1, EpCAM and EGFR in urine 
samples collected at the time of diagnosis (after diagnostic 
cystoscopy, prior to TURBT) represents assessment of 
biological processes associated with BC pathogenesis, 
and the subsequent risk of disease-specific death. Given 
that we demonstrated a weaker association for NMIBC 
progression (to MIBC) than for mortality, it is likely that 
these processes predominate later in disease pathogenesis, 
and are possibly related to the development of metastases. 
This is supported by the observation that these proteins 
remain prognostic when measured in the urine of patients 
already diagnosed with MIBC. 
Despite extensive efforts at the genomic, epigenomic 
and transcriptomic analysis of high-risk NMIBC, no 
validated tissue-based prognostic biomarkers have 
emerged. We suggest that urinary HAI-1 and EpCAM 
could be used to facilitate decision-making regarding the 
treatment of patients with high-risk NMIBC – a simple 
stratification tool, with an elevated test guiding patients 
and clinicians towards more radical therapy instead 
of bladder preservation. Furthermore, recruiting and 
randomising BC patients to trials of bladder preservation 
versus radical cystectomy is notoriously difficult [18]. 
In these settings, one should have the strongest rationale 
possible (i.e. death from disease) to counsel or stratify 
patients towards one treatment modality or the other. 
Urinary biomarkers such as HAI-1 and EpCAM may 
be useful tools for facilitating such patient counselling, 
recruitment and randomisation.
For MIBC, the clinical utility of our biomarkers 
for patient and treatment stratification is less obvious. 
We caution against over-interpretation since these were 
exploratory analyses; we would have liked to adjust for 
more appropriate risk factors had they been available, but 
BCPP is a NMIBC-focused study [16]. However, these 
data do align with our findings in high-risk NMIBC, as 
discussed above.
We appreciate that there are limitations to this 
study. We chose an arbitrary cutpoint to define an elevated 
Figure 3: Overall survival curves for normal and elevated biomarker test results for (A) EGFR, (B) EpCAM, (C) HAI-1 and (D) 
combination of all three biomarkers, within each EAU risk group in NMIBC patients.
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test result (upper quartile); however, we felt that this 
approximated to the proportion of UK patients who undergo 
cystectomy as the initial primary treatment of high-risk 
NMIBC (c.25%). The number of progression events and 
BC-deaths were also low, resulting in low power to detect 
associations. However, although not always statistically 
significant, the direction of associations was consistent 
for the biomarkers with each of the outcomes, and within 
NMIBC and MIBC groups. Also due to the low number of 
events, we could not include many variables in the models 
individually and decided to simply adjust for EAU NMIBC 
risk group. Future work in larger cohorts with more events 
should additionally adjust for other potential confounders. 
In addition, treatment data for high-risk NMIBC patients 
were reported inconsistently and we could not analyse 
them reliably, nor incorporate the data into multivariable 
analyses; however, a simple observational analysis using 
the data that were recorded suggested similar proportions of 
normal and elevated biomarker levels within each treatment 
category and a low probability of influencing the biomarker 
relationships observed. Clearly, validation in an independent 
cohort is required as the next step of translation, alongside 
further work to determine a suitable biomarker cut-off value 
that assists treatment decisions. 
Furthermore, since patients’ biospecimens were 
only collected at the time of diagnosis, it remains 
unknown whether these biomarkers also have prognostic 
utility when applied at the time of NMIBC recurrence 
or progression. Finally, further evaluation of these 
biomarkers is required in MIBC patients as the clinical 
utility is less obvious than for NMIBC.
PATIENTS AND METHODS
Patients and biospecimens
Urine samples were obtained from the prospective 
BCPP biospecimen collection (ethics approval 06/
MRE04/65) [16]. Patients were recruited between 2005 
and 2011 from nine hospitals in the West Midlands region, 
and gave informed consent for enrolment into BCPP on 
the basis of initial cystoscopic findings suggestive of 
primary BC. All patients were newly-diagnosed, had not 
received BC treatment prior to biospecimen collection, 
and were subsequently treated and followed-up according 
to contemporary guidelines (including re-resection where 
indicated). Inclusion and exclusion criteria are detailed 
elsewhere [16].
Urine samples were obtained prior to transurethral 
resection of bladder tumour(s) (TURBT) specifically for 
biomarker analyses [16]. Samples were placed on ice, 
centrifuged at 2000 rpm for 10 minutes within 8 hours 
of collection, and supernatants and pellets separated and 
stored at −80° C. 
Tumour grade and stage records were amended 
according to results of re-resection or cystectomy (where 
performed). We used the 1973 grade classification as 
it was in universal use in the UK at the time of patient 
recruitment, and is also the basis for the EORTC and 
EAU NMIBC risk tables [1, 3]. Diagnostic formalin-fixed 
paraffin-embedded tumour samples were retrieved from 
local histopathology departments, and 10% of all such 
samples underwent expert pathological review as part 
of routine quality assurance. All included tumours were 
purely or predominantly transitional cell carcinomas.
ELISAs
ELISAs were performed as previously described 
[12–14]. Briefly, 20–50 µl of urine supernatant was 
diluted in phosphate buffered saline containing 1% 
bovine serum albumin and analysed using DuoSet 
sandwich ELISAs (R&D Systems, catalogue numbers 
DY231, DY960, DY1048). Urine samples were randomly 
assigned to ELISA plates and QA samples used to verify 
the consistency of results across plates. Urinary protein 
concentrations were normalised to urinary creatinine.
Statistical analyses
Our previous work analysed urine samples for 
HAI-1, EpCAM and EGFR levels in subsets of patients 
Table 4: Cox model estimates for biomarkers from univariable (unadjusted) and multivariable models in MIBC 
patients (N = 175)
BC-specific mortality All-cause mortality
Unadjusted Adjusted+ Unadjusted Adjusted+
HR* (95% CI) P-value HR* (95% CI) P-value HR* (95% CI) P-value HR* (95% CI) P-value
Elevated EGFR 1.57 
(1.01 to 2.44) 0.043
1.62 
(1.02 to 2.58) 0.040
1.66 
(1.16 to 2.39) 0.006
1.75 
(1.19 to 2.56) 0.004
Elevated 
EpCAM
1.47 
(0.95 to 2.25) 0.080
1.38 
(0.88 to 2.18) 0.163
1.35 
(0.95 to 1.92) 0.089
1.33 
(0.92 to 1.93) 0.132
Elevated HAI-1 2.62 
(1.62 to 4.23) <0.001
2.59 
(1.58 to 4.23) <0.001
2.11 
(1.45 to 3.08) <0.001
2.12 
(1.44 to 3.13) <0.001
Any biomarker 
elevated
4.40 
(1.90 to 10.17) 0.001
4.30 
(1.85 to 10.03) 0.001
3.06 
(1.68 to 5.58) <0.001
3.07 
(1.67 to 5.63) <0.001
*Hazard ratios are relative to baseline categories which are EAU low risk, normal EGFR, normal EpCAM and normal HAI-1.
+Adjusted for grade, size of tumour, single or multiple tumours and CIS.
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[12–14]. In the current study, we repeated the analyses 
of all 3 biomarkers in more patients using data from a 
new series of biomarker assays conducted in duplicate. 
Figure 1 shows the exclusions made and final number of 
individuals used in the analysis.
Individuals were excluded from analysis if they 
were determined to not have bladder cancer or it was 
unknown. A complete case analysis was used; therefore, 
individuals were also excluded if they did not have 
biomarker measurements, were missing follow-up 
information, or were missing risk factor information 
for stage, grade, size, number of tumours, or presence 
or absence of CIS. Individuals with solitary CIS were 
excluded. Biomarkers were measured in all patients 
who provided a sufficient volume of urine for analysis; 
however, patient characteristics were compared between 
patients with and without biomarker measurements 
(Supplementary Table 10). 
Three outcomes were considered: progression to 
MIBC (for NMIBC patients), bladder cancer specific 
mortality and all-cause mortality. Survival times were 
calculated from the date of registration into the BCPP 
study until the date of progression, date of death (for all-
cause mortality), or date of death from bladder cancer 
(for bladder cancer specific mortality). Individuals were 
censored at the date last known to be progression-free (for 
progression), alive, or additionally at the date of death 
from other causes for bladder cancer specific mortality.
Patient characteristics were summarised using 
frequencies and percentages for categorical variables 
and medians with interquartile ranges (IQR) for skewed 
continuous variables. Follow-up was summarised using 
the median duration and 95% confidence interval (CI) for 
the median.
For each biomarker, the cut-off for an elevated result 
was set at the 75th percentile of all values within NMIBC 
patients, therefore fixing 25% of NMIBC patients to be 
‘elevated’ and approximating to the proportion of UK 
patients who undergo cystectomy as the initial primary 
treatment of high-risk NMIBC. Patients were categorised 
into EAU risk groups (low, intermediate and high) [1]. 
Kaplan-Meier survival curves were plotted to compare 
normal and elevated values for each biomarker in all 
NMIBC patients, as well as within each EAU risk group. 
Univariable Cox proportional hazards models were fitted 
to estimate the associations between each biomarker 
(elevated versus normal) and outcome (either progression, 
bladder cancer specific mortality or all-cause mortality). 
Biomarkers were also investigated in combination (if any 
of EGFR, EpCAM or HAI-1 were elevated). Additionally, 
multivariable Cox models were fitted, adjusting for EAU 
risk group. As patients were recruited from multiple 
centres, all Cox models included a shared frailty term 
to account for within-centre clustering. The proportional 
hazards assumption was checked using log-log plots for 
all variables included in any of the models and for all 
outcomes. Hazard ratios and 95% CIs are reported for 
each biomarker, including both unadjusted and adjusted 
(for EAU risk group) results.
The biomarkers were also evaluated in MIBC 
patients using Kaplan-Meier plots and Cox models as for 
NMIBC patients. However, EAU risk groups are specific 
to NMIBC patients; therefore, in the multivariable models, 
adjustment was made for the individual factors that make 
up the EAU risk groups: stage, grade, size, number of 
tumours and presence or absence of CIS.
Principal treatment was summarised for the high-
risk NMIBC group using frequencies and percentages for 
normal and elevated values for each biomarker.
Statistical analyses were performed using Stata MP 
14.0 (StataCorp, College Station, TX, USA).
CONCLUSIONS
Elevated levels of urinary HAI-1 and EpCAM are 
independent prognostic factors for BC-specific survival 
in NMIBC patients, and may be useful for informing 
both clinician and patient decisions regarding the initial 
management of HR-NMIBC by primary cystectomy or 
bladder-preservation.
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